Stocks
Novo Nordisk (NVO) EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA | ? | 65 394 000 000 | 76 802 000 000 | 114 629 000 000 | 147 938 000 000 | 156 729 000 000 | 181 540 000 000 | ||
| Changes by years, y/y, % | +10% | +17% | +49% | +29% | +6% | +21.5% | |||
Novo Nordisk. EBITDA US GAAP
Novo Nordisk. EBITDA US GAAP, changes, %
Novo Nordisk. EBITDA US GAAP, sum by quarters
Novo Nordisk (NVO) EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA | ? | 46 046 000 000 | 43 596 000 000 | 31 439 000 000 | 37 298 000 000 | 69 207 000 000 | 181 540 000 000 | |
| Changes by years, y/y, % | +25% | +22% | -16% | -19% | +50% | |||
| Changes by quarters, q/q, % | +0% | -5% | -28% | +19% | +86% | |||
